Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene -: Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer

被引:197
作者
Vasey, PA
Shulman, LN
Campos, S
Davis, J
Gore, M
Johnston, S
Kirn, DH
O'Neill, V
Siddiqui, N
Seiden, MV
Kaye, SB
机构
[1] Beatson Oncol Ctr, Canc Res Campaign, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland
[2] Stobhill Gen Hosp, Glasgow G21 3UW, Lanark, Scotland
[3] Royal Marsden Hosp, Surrey, England
[4] Univ London Imperial Coll Sci Technol & Med, London, England
[5] Imperial Canc Res Fund, London WC2A 3PX, England
[6] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词
D O I
10.1200/JCO.20.6.1562
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Resistance to chemotherapy in ovarian cancer is frequently associated with mutations in the p53 gene. The adenovirus dl1520 (ONYX-015) with the EIS 55-kd gene deleted, allowing selective replication in and lysis of p53-deficient tumor cells, has shown preclinical efficacy against p53-deficient nude mouse-human ovarian carcinomatosis xenografts. Patients and Methods: We undertook a phase I trial of intraperitoneal dl1520 in patients with recurrent ovarian cancer. Sixteen women with recurrent/refractory ovarian cancer received 35 cycles (median, two cycles) of dl1520 delivered on days 1 through 5 in four dose cohorts: 1 x 10(9) plaque forming units (pfu), 1 x 10(10) pfu, 3 x 10(10) pfu, and 1 x 10(11) pfu. Results: The most common significant toxicities related to virus administration were flu-like symptoms, emesis, and abdominal pain. One patient receiving 1 x 10(10) pfu developed common toxicity criteria grade 3 abdominal pain and diarrhea, which was dose-limiting. The maximum-tolerated dose was not reached at 10(11) pfu, and at this dose level patients did not experience significant toxicity. There was no clear-cut evidence of clinical or radiologic response in any patient. Blood samples were taken for adenovirus DNA and neutralizing antibodies. Polymerase chain reaction data indicating presence of virus up to 10 days after the final (day 5) infusion of dl1520 are suggestive of continuing viral replication. Conclusion: This article therefore describes the first clinical experience with the intraperitoneal delivery of any replication-competent/-selective virus in cancer patients.
引用
收藏
页码:1562 / 1569
页数:8
相关论文
共 36 条
[1]  
BAXTER LT, 1994, CANCER RES, V54, P1517
[2]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[3]  
BOYLE JO, 1993, CANCER RES, V53, P4477
[4]   Estimates of cancer incidence and mortality in Europe in 1995 [J].
Bray, F ;
Sankila, R ;
Ferlay, J ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) :99-166
[5]   Up date in the management of advanced ovarian carcinoma [J].
Conte, PF ;
Cianci, C ;
Gadducci, A .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 32 (01) :49-58
[6]   WILD-TYPE P53 MEDIATES APOPTOSIS BY E1A, WHICH IS INHIBITED BY E1B [J].
DEBBAS, M ;
WHITE, E .
GENES & DEVELOPMENT, 1993, 7 (04) :546-554
[7]   Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients [J].
Eisenhauer, EA ;
Vermorken, JB ;
vanGlabbeke, M .
ANNALS OF ONCOLOGY, 1997, 8 (10) :963-968
[8]  
Ganly I, 2000, CLIN CANCER RES, V6, P798
[9]  
GANLY I, IN PRESS GENE THERAP
[10]   p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection [J].
Goodrum, FD ;
Ornelles, DA .
JOURNAL OF VIROLOGY, 1998, 72 (12) :9479-9490